Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection.
about
The RD114/simian type D retrovirus receptor is a neutral amino acid transporterThe NV gene of snakehead rhabdovirus (SHRV) is not required for pathogenesis, and a heterologous glycoprotein can be incorporated into the SHRV envelopeTargeted infection of HIV-1 Env expressing cells by HIV(CD4/CXCR4) vectors reveals a potential new rationale for HIV-1 mediated down-modulation of CD4Attenuated vesicular stomatitis viruses as vaccine vectorsCharacterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins.Cryo-EM Model of the Bullet-Shaped Vesicular Stomatitis VirusVesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection.A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge.In Vitro and In Vivo Attenuation of Vesicular Stomatitis Virus (VSV) by Phosphoprotein Deletion.Viral strategies for studying the brain, including a replication-restricted self-amplifying delta-G vesicular stomatis virus that rapidly expresses transgenes in brain and can generate a multicolor golgi-like expressionModeling HIV quasispecies evolutionary dynamics.Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccinesParamyxovirus replication and pathogenesis. Reverse genetics transforms understanding.Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression.Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.Paramyxovirus reverse genetics is coming of age.Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challengeIdentification of the respiratory syncytial virus proteins required for formation and passage of helper-dependent infectious particles.The membrane-proximal stem region of vesicular stomatitis virus G protein confers efficient virus assembly.N-linked glycosylation of CXCR4 masks coreceptor function for CCR5-dependent human immunodeficiency virus type 1 isolates.Retroviral vector targeting to human immunodeficiency virus type 1-infected cells by receptor pseudotypingA cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression.Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.Recombinant Newcastle disease virus as a vaccine vectorA GP64-null baculovirus pseudotyped with vesicular stomatitis virus G proteinA single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector.Chemokines and their receptors in infectious disease.Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoproteinHeterologous exchanges of the glycoprotein and the matrix protein in a Novirhabdovirus.Roles for the cytoplasmic tails of the fusion and hemagglutinin-neuraminidase proteins in budding of the paramyxovirus simian virus 5.Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease.The membrane-proximal domain of vesicular stomatitis virus G protein functions as a membrane fusion potentiator and can induce hemifusionEffectiveness of a 'hunter' virus in controlling human immunodeficiency virus type 1 infection.Complementing defective viruses that express separate paramyxovirus glycoproteins provide a new vaccine vector approach.Organization of the vesicular stomatitis virus glycoprotein into membrane microdomains occurs independently of intracellular viral components.Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response.A biosensor assay for studying ligand-membrane receptor interactions: binding of antibodies and HIV-1 Env to chemokine receptorsRabies virus nucleoprotein as a carrier for foreign antigens.
P2860
Q22008840-68CB935B-CC53-4A11-BFEA-E1C48622D10DQ24563525-E84E3850-40A4-4CD6-B8DF-64C1817D37C6Q25257643-42DD2A99-636B-40B8-91E4-AD074D784159Q27469358-205717E7-AEEF-47E2-9970-3C5320BB09E0Q27472885-68BEED62-4F7E-4382-B404-656E7A11E304Q27659534-ACCAEEA5-3303-467C-90CC-405B83C7EDCFQ30361939-93BB13C9-FAD5-4257-AF71-D4D0ADE49997Q30370147-35FD4C43-0A03-4D23-AC01-73632891C845Q30382576-5B337D64-5197-46C3-AFAC-E59D7D64E9D5Q30385999-218927E4-F750-4AB2-83D0-3FB7770E0AE3Q30389455-9433FE02-D470-40CA-9723-616ED4E8B3D0Q30495981-1D996DDD-1A33-41D0-97D3-8E74074F2BABQ33296550-6B79FDC8-4DF3-4941-BC83-91FCBA328DDEQ33657931-F1FA31A1-67C3-44BA-AD9D-260D7A74B2C0Q33673962-105DFD38-DFD7-46F7-8423-8C8971258D49Q33721746-48587B8E-A3CA-4AEA-A4BE-9273C0D1AEBBQ33725635-5C7544BF-6A08-44B4-9E22-5DEAA0B4E64AQ33755770-624C8916-C24A-4FB9-91B9-9A64598D6C99Q33783986-0442AFD0-4F44-443C-8B40-2ADF6DC4564FQ33785124-A5136E7F-EF75-4BD4-A2B7-F690BFF9A012Q33798704-FFA2F7AD-634D-408A-986D-73341840C6EFQ33804016-B04C491A-92C8-4DDB-B16D-A3C3AA0744D3Q33804059-EA5B9FB9-8076-400E-9196-EDB697FA62C4Q33808044-3B9B7B58-C892-4E33-8F5C-26EE420FE272Q33849224-87F7871C-689D-46E7-9C5D-73F6E2449691Q33850246-A08ECCF7-F780-4B7B-BBFC-FFA67363BB6BQ33865069-580761B1-FAD2-4689-9E93-5CE0408EA2EFQ34092753-B6E925AD-38D7-4841-BD98-A7D5CF6AFDF4Q34129756-942D09A0-4C4E-49DE-9A08-3C0B97018677Q34329802-EF48888B-0A49-4B55-9B9B-7514E8E5D7ECQ34332631-F1CBFEBC-E51E-493E-ACEE-907B601670D6Q34345181-2FEDEDD4-C6A7-4104-B4CC-7DEE2BD9DE0CQ34357917-FA7B4CD0-14D4-48D3-8688-7D195DF653EBQ34358880-D8B56C13-F489-4C8E-A42C-378B77E79CB4Q34641904-A43D36E1-C0E7-4201-80AB-421DD10DA70DQ34741896-608A102C-6AD7-4F93-99DD-953B54CE0751Q34781925-1B1B0664-84AA-49B7-99D2-06C18D997CDEQ34998032-72DDDCB0-07A1-4965-BBB0-3B4A7C4FA82DQ35263959-7B6B4A85-5AEE-4F6D-80DD-53C102B14912Q35320069-B4C1289A-49CD-4E54-A13D-D9D52ABC321D
P2860
Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Construction of a novel virus ...... and controls HIV-1 infection.
@en
type
label
Construction of a novel virus ...... and controls HIV-1 infection.
@en
prefLabel
Construction of a novel virus ...... and controls HIV-1 infection.
@en
P2093
P1433
P1476
Construction of a novel virus ...... and controls HIV-1 infection.
@en
P2093
P304
P356
10.1016/S0092-8674(00)80350-5
P407
P577
1997-09-01T00:00:00Z